

Clinician Input to the pan-Canadian Oncology Drug Review (pCODR)

OVERVIEW

Since February 2016 pCODR allows clinicians to provide input and feedback and participate in the pCODR process

- pCODR updated the clinician input process in 2018, expanding the process to include oncology physicians, pharmacists and nurses.

This initiative allows for broader clinician participation in providing and enhancing value-added information in the discussion of drug funding decisions in Canada.

- Clinicians can provide valuable information, based on their clinical experience, about the need for and use of new cancer drug therapies.


Information about the clinician input process is available here:

www.cadth.ca/clinician-input-and-feedback

Guidelines, procedures and templates for clinicians are available

here: www.cadth.ca/cadth-procedures-reimbursement-reviews

HOW DOES A CLINICIAN PROVIDE INPUT?



STEP 1: REGISTRATION

Clinicians must register online at: www.cadth.ca/cadth-collaborative-workspaces-registration

An eligible registrant must meet the following requirements:

1. is an actively practising oncologist (or a physician who treats cancer patients), oncology pharmacist, or oncology nurse; and
2. submits a declaration of conflict of interest.

Note: The input from an oncology pharmacist and oncology nurse must be part of a joint submission with a registered oncologist or physician who treats cancer patients.

STEP 2: CLINICIAN INPUT

Registered clinicians will receive email notification from CADTH/pCODR of all upcoming reviews at pCODR one month prior to manufacturer's submission.

The email notification will have information pertaining to the drug and indication under review, the link to the clinician input template, and the deadline date for submitting.

The registered clinician must use the drug specific template:

- Key questions for clinician input include:
 - Current treatments for indication under review
 - Eligible patient population
 - Relevance to clinical practice
 - Sequencing and priority of treatments
 - Companion diagnostic testing
 - Additional questions specific to the drug and indication under review

STEP 3: CLINICIAN FEEDBACK

Clinicians will receive emails from CADTH/pCODR when initial recommendations are posted.

Only clinicians who provided input at the beginning of the process may provide feedback on the initial recommendation.

Clinician feedback will be considered when making the Final Recommendation.

The registered clinician must use the "Stakeholder Feedback on a pCODR Expert Review Committee Initial Recommendation" template accessed at:

www.cadth.ca/stakeholder-feedback